Organigram Holdings Inc.

NasdaqGS:OGI Stock Report

Market Cap: US$161.0m

Organigram Holdings Valuation

Is OGI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OGI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OGI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OGI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OGI?

Key metric: As OGI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OGI. This is calculated by dividing OGI's market cap by their current revenue.
What is OGI's PS Ratio?
PS Ratio1.5x
SalesCA$149.21m
Market CapCA$225.86m

Price to Sales Ratio vs Peers

How does OGI's PS Ratio compare to its peers?

The above table shows the PS ratio for OGI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.2x
FULC Fulcrum Therapeutics
2.6x-91.5%US$191.5m
SCPH scPharmaceuticals
6.2x45.2%US$180.1m
MDWD MediWound
9.5x38.8%US$182.4m
NKTR Nektar Therapeutics
2.2x11.8%US$197.4m
OGI Organigram Holdings
1.5x16.5%US$225.9m

Price-To-Sales vs Peers: OGI is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (5.2x).

Price to Sales Ratio vs Industry

How does OGI's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$4.07b
PRGO Perrigo
0.9x3.4%US$3.87b
BHC Bausch Health Companies
0.3x1.5%US$2.90b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.56b
OGI 1.5xIndustry Avg. 3.0xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OGI is good value based on its Price-To-Sales Ratio (1.5x) compared to the US Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is OGI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OGI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: OGI is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OGI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.50
US$2.61
+74.2%
26.7%US$3.85US$1.84n/a6
Nov ’25US$1.73
US$2.61
+51.0%
26.7%US$3.85US$1.84n/a6
Oct ’25US$1.76
US$2.61
+48.5%
26.7%US$3.85US$1.84n/a6
Sep ’25US$1.85
US$2.68
+44.8%
25.1%US$3.83US$1.82n/a7
Aug ’25US$1.57
US$2.66
+69.5%
25.8%US$3.86US$1.84n/a7
Jul ’25US$1.54
US$2.66
+72.8%
25.8%US$3.86US$1.84n/a7
Jun ’25US$1.71
US$2.66
+55.6%
25.8%US$3.86US$1.84n/a7
May ’25US$1.92
US$2.68
+40.2%
25.1%US$3.81US$1.81n/a7
Apr ’25US$2.06
US$2.59
+26.0%
29.1%US$4.06US$1.85n/a7
Mar ’25US$2.16
US$2.51
+16.1%
29.9%US$4.07US$1.85n/a8
Feb ’25US$1.83
US$2.48
+35.5%
37.3%US$4.13US$1.50n/a8
Jan ’25US$1.31
US$2.47
+88.8%
37.3%US$4.11US$1.50n/a8
Dec ’24US$1.34
US$2.76
+105.7%
36.9%US$4.79US$1.47n/a8
Nov ’24US$1.03
US$2.76
+167.6%
36.9%US$4.79US$1.47US$1.738
Oct ’24US$1.32
US$2.76
+108.8%
36.9%US$4.79US$1.47US$1.768
Sep ’24US$1.54
US$2.86
+85.7%
34.6%US$4.93US$1.52US$1.859
Aug ’24US$1.49
US$2.86
+91.9%
34.6%US$4.93US$1.52US$1.579
Jul ’24US$1.56
US$4.43
+183.9%
31.6%US$6.64US$2.95US$1.5410
Jun ’24US$1.56
US$4.43
+183.9%
31.6%US$6.64US$2.95US$1.7110
May ’24US$1.96
US$4.43
+125.9%
31.6%US$6.64US$2.95US$1.9210
Apr ’24US$2.56
US$5.97
+133.3%
27.4%US$9.58US$3.83US$2.0611
Mar ’24US$3.02
US$5.97
+97.6%
27.4%US$9.58US$3.83US$2.1611
Feb ’24US$3.79
US$6.11
+61.1%
26.9%US$9.71US$3.88US$1.8311
Jan ’24US$3.20
US$6.62
+106.9%
26.1%US$9.56US$4.41US$1.3111
Dec ’23US$4.40
US$6.85
+55.7%
25.5%US$9.66US$4.46US$1.3411
Nov ’23US$4.04
US$7.23
+78.9%
24.2%US$9.59US$4.43US$1.0311

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.71

7D

2.4%

1Y

20.0%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$59.39

7D

7.8%

1Y

20.6%

IQVIA Holdings

US$36.5b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.43

7D

3.6%

1Y

-5.8%